Marin H Kollef

List of Publications by Year
in descending order

369 papers	42,545 citations	1911 102 h-index	2358 198 g-index
389 all docs	389 docs citations	389 times ranked	25585 citing authors

#	Article	IF	Citations
1	Comparison of Empiric Antibiotic Treatment Regimens for Hospitalized, Non-severe Community-acquired Pneumonia: A Retrospective, Multicenter Cohort Study. Clinical Therapeutics, 2024, 46, 338-344.	2.3	0
2	The importance of viruses in ventilator-associated pneumonia. Infection Control and Hospital Epidemiology, 2023, 44, 1137-1142.	2.0	4
3	Clinician Perspectives on Barriers and Enablers to Implementing an Inpatient Oncology Early Warning System: A Mixed-Methods Study. JCO Clinical Cancer Informatics, 2023, , .	2.2	1
4	Addition of aminoglycosides reduces recurrence of infections with multidrug-resistant Gram-negative bacilli in patients with sepsis and septic shock. International Journal of Antimicrobial Agents, 2023, 62, 106913.	3.3	0
5	Race Does Not Impact Sepsis Outcomes When Considering Socioeconomic Factors in Multilevel Modeling. Critical Care Medicine, 2022, 50, 410-417.	0.9	6
6	Infection control in the intensive care unit: expert consensus statements for SARS-CoV-2 using a Delphi method. Lancet Infectious Diseases, The, 2022, 22, e74-e87.	8.9	12
7	Prospective Nasal Screening for Methicillin-Resistant Staphylococcus aureus in Critically Ill Patients With Suspected Pneumonia. Open Forum Infectious Diseases, 2022, 9, ofab578.	0.9	3
8	Clinical and microbiological outcomes, by causative pathogen, in the ASPECT-NP randomized, controlled, Phase 3 trial comparing ceftolozane/tazobactam and meropenem for treatment of hospital-acquired/ventilator-associated bacterial pneumonia. Journal of Antimicrobial Chemotherapy, 2022, 77, 1166-1177.	3.2	8
9	Classical and Molecular Techniques to Diagnose HAP/VAP. Seminars in Respiratory and Critical Care Medicine, 2022, 43, 219-228.	2.2	3
10	Life-Threatening Infections: Pulmonary and Systemic Infections. Seminars in Respiratory and Critical Care Medicine, 2022, 43, 001-002.	2.2	1
11	Impact of Stress Ulcer Prophylaxis Discontinuation Guidance in Mechanically Ventilated, Critically Ill Patients: A Pre-Post Cohort Study. Hospital Pharmacy, 2022, 57, 510-517.	0.9	3
12	How to use new antibiotics in the therapy of ventilator-associated pneumonia. Current Opinion in Infectious Diseases, 2022, 35, 140-148.	3.1	1
13	Mechanical Ventilation Practices and Low Tidal Volume Ventilation in Air Medical Transport Patients: The AIR-VENT Study. Respiratory Care, 2022, 67, 647-656.	1.8	1
14	Ceftriaxone resistance and adequacy of initial antibiotic therapy in community onset bacterial pneumonia. Medicine (United States), 2022, 101, e29159.	1.1	1
15	Î²-Lactam Therapeutic Drug Monitoring in Critically Ill Patients: Weighing the Challenges and Opportunities to Assess Clinical Value. , 2022, 4, e0726.		16
16	Lack of pathogen identification influencing antibiotic de-escalation in hospital-acquired pneumonia. Antimicrobial Stewardship & Healthcare Epidemiology, 2022, 2, .	0.5	0
17	Next Steps in Pneumonia Severity Scores. Clinical Infectious Diseases, 2021, 72, 950-952.	5.7	3
18	Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infectious Diseases, The, 2021, 21, 213-225.	8.9	281

#	Article	IF	Citations
19	Short-Term Effects of Appropriate Empirical Antimicrobial Treatment with Ceftolozane/Tazobactam in a Swine Model of Nosocomial Pneumonia. Antimicrobial Agents and Chemotherapy, 2021, 65, .	3.4	1
20	Racial Disparities in Readmissions Following Initial Hospitalization for Sepsis. Critical Care Medicine, 2021, 49, e258-e268.	0.9	13
21	Nosocomial Infection. Critical Care Medicine, 2021, 49, 169-187.	0.9	106
22	Pneumococcal community-acquired pneumonia in the intensive care unit: Azithromycin remains protective despite macrolide resistance. Respiratory Medicine, 2021, 177, 106307.	2.9	6
23	Comparison of Sepsis Definitions as Automated Criteria. Critical Care Medicine, 2021, 49, e433-e443.	0.9	16
24	Characteristics of U.S. Acute Care Hospitals That Have Implemented Telemedicine Critical Care. , 2021, 3, e0468.		18
25	A Pragmatic Machine Learning Model To Predict Carbapenem Resistance. Antimicrobial Agents and Chemotherapy, 2021, 65, e0006321.	3.4	14
26	New Perspectives on Antimicrobial Agents: Ceftolozane-Tazobactam. Antimicrobial Agents and Chemotherapy, 2021, 65, e0231820.	3.4	19
27	Initial antimicrobial management of sepsis. Critical Care, 2021, 25, 307.	6.0	78
28	Ceftolozane/tazobactam versus meropenem in patients with ventilated hospital-acquired bacterial pneumonia: subset analysis of the ASPECT-NP randomized, controlled phase 3 trial. Critical Care, 2021, 25, 290.	6.0	25
29	Monoclonal antibodies as antibacterial therapies: thinking outside of the box. Lancet Infectious Diseases, The, 2021, 21, 1201-1202.	8.9	8
30	Spot the difference: comparing results of analyses from real patient data and synthetic derivatives. JAMIA Open, 2021, 3, 557-566.	2.1	36
31	Timing of antibiotic therapy in the ICU. Critical Care, 2021, 25, 360.	6.0	69
32	Ceftolozane/tazobactam probability of target attainment and outcomes in participants with augmented renal clearance from the randomized phase 3 ASPECT-NP trial. Critical Care, 2021, 25, 354.	6.0	15
33	Short- Versus Standard-Course Nonmacrolide Antibiotic Treatment in Acute Exacerbations of Chronic Obstructive Pulmonary Disease: A Retrospective, Observational Cohort Study. Clinical Therapeutics, 2021, , .	2.3	1
34	The Epidemiology and Pathogenesis and Treatment of Pseudomonas aeruginosa Infections: An Update. Drugs, 2021, 81, 2117-2131.	11.1	234
35	Assessment of Antibiotic De-escalation by Spectrum Score in Patients With Nosocomial Pneumonia: A Single-Center, Retrospective Cohort Study. Open Forum Infectious Diseases, 2021, 8, ofab508.	0.9	11
36	Vancomycin/Piperacillin-tazobactam Nephrotoxicity in the Critically Ill. Clinical Infectious Diseases, 2020, 70, 1520-1521.	5.7	3

#	Article	IF	Citations
37	Doripenem for treating nosocomial pneumonia and ventilator-associated pneumonia â€“ Authors' reply. Lancet Infectious Diseases, The, 2020, 20, 20-21.	8.9	0
38	Impact of Baseline Characteristics on Future Episodes of Bloodstream Infections: Multistate Model in Septic Patients With Bloodstream Infections. Clinical Infectious Diseases, 2020, 71, 3103-3109.	5.7	4
39	Microbiologic Failure Despite Clinical Cure in Pneumonia: Cum Hoc and Post Hoc Ergo Propter Hoc. Clinical Infectious Diseases, 2020, 71, 3042-3043.	5.7	0
40	Antimicrobial de-escalation in critically ill patients: a position statement from a task force of the European Society of Intensive Care Medicine (ESICM) and European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Critically Ill Patients Study Group (ESGCIP). Intensive Care Medicine, 2020, 46, 245-265.	8.2	109
41	Healthcare Resource Utilization of Ceftolozane/Tazobactam Versus Meropenem for Ventilated Nosocomial Pneumonia from the Randomized, Controlled, Double-Blind ASPECT-NP Trial. Infectious Diseases and Therapy, 2020, 9, 953-966.	4.1	4
42	A PRAGMATIC MACHINE LEARNING MODEL TO PREDICT CARBAPENEM RESISTANCE. Chest, 2020, 158, A706.	0.9	1
43	Culture-negative sepsis. Current Opinion in Critical Care, 2020, 26, 473-477.	3.4	28
44	Bacterial and fungal superinfections in critically ill patients with COVID-19. Intensive Care Medicine, 2020, 46, 2071-2074.	8.2	89
45	Limitations of Registration Trials for Nosocomial Pneumonia. Clinical Infectious Diseases, 2020, 73, e4549-e4551.	5.7	2
46	Pulmonary infections complicating ARDS. Intensive Care Medicine, 2020, 46, 2168-2183.	8.2	85
47	Characteristics and outcomes among a hospitalized patient cohort with Streptococcus pneumoniae infection. Medicine (United States), 2020, 99, e20145.	1.1	4
48	Bloodstream Infections and Delayed Antibiotic Coverage Are Associated With Negative Hospital Outcomes in Hematopoietic Stem Cell Transplant Recipients. Chest, 2020, 158, 1385-1396.	0.9	6
49	Prevalence and Outcomes of Infection Among Patients in Intensive Care Units in 2017. JAMA - Journal of the American Medical Association, 2020, 323, 1478.	7.0	480
50	PROPHETIC. Chest, 2020, 158, 2370-2380.	0.9	19
51	Evaluation of a ceiling effect on the association of new resistance development to antipseudomonal beta-lactam exposure in the critically ill. Infection Control and Hospital Epidemiology, 2020, 41, 484-485.	2.0	9
52	1477. Impact Of Resistance Thresholds On Mortality In Hospital-Acquired And Ventilator-Associated Pneumonia. Open Forum Infectious Diseases, 2020, 7, S739-S740.	0.9	0
53	Pathogen-Negative Sepsisâ€"An Opportunity for Antimicrobial Stewardship. Open Forum Infectious Diseases, 2019, 6, ofz397.	0.9	10
54	Ceftolozaneâ€“tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial. Lancet Infectious Diseases, The, 2019, 19, 1299-1311.	8.9	230

#	Article	IF	Citations
55	Outcomes of Macrolide Deescalation in Severe Community-acquired Pneumonia. Clinical Therapeutics, 2019, 41, 2540-2548.	2.3	7
56	Redefining the Threshold for Broad-Spectrum Antibiotics. Annals of the American Thoracic Society, 2019, 16, 1367-1369.	3.6	0
57	Novel Approaches to Hasten Detection of Pathogens and Antimicrobial Resistance in the Intensive Care Unit. Seminars in Respiratory and Critical Care Medicine, 2019, 40, 454-464.	2.2	12
58	Challenges in severe community-acquired pneumonia: a point-of-view review. Intensive Care Medicine, 2019, 45, 159-171.	8.2	108
59	Rebuttal From Drs AguilarÂand Kollef. Chest, 2019, 155, 668-669.	0.9	0
60	Reduction in antimicrobial use among medical intensive care unit patients during a cluster randomized crossover trial of palliative care consultation. Infection Control and Hospital Epidemiology, 2019, 40, 491-492.	2.0	3
61	POINT: Does Persistent or Worsening ARDS Refractory to Optimized Ventilation and Proning Deserve a Trial of Prostacyclin? Yes. Chest, 2019, 155, 662-665.	0.9	5
62	Clinical Effect of Expedited Pathogen Identification and Susceptibility Testing for Gram-Negative Bacteremia and Candidemia by Use of the Accelerate PhenoTM System. journal of applied laboratory medicine, The, 2019, 3, 569-579.	1.2	17
63	Elaboration of Consensus Clinical Endpoints to Evaluate Antimicrobial Treatment Efficacy in Future Hospital-acquired/Ventilator-associated Bacterial Pneumonia Clinical Trials. Clinical Infectious Diseases, 2019, 69, 1912-1918.	5.7	27
64	Incidence of Acute Kidney Injury in Critically Ill Patients Receiving Vancomycin with Concomitant Piperacillin-Tazobactam, Cefepime, or Meropenem. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.4	59
65	Moving the Practice of Respiratory Therapy Forward. Respiratory Care, 2019, 64, 1014-1016.	1.8	1
66	Early Palliative Care Consultation in the Medical ICU: A Cluster Randomized Crossover Trial. Critical Care Medicine, 2019, 47, 1707-1715.	0.9	102
67	Cluster analysis to define distinct clinical phenotypes among septic patients with bloodstream infections. Medicine (United States), 2019, 98, e15276.	1.1	19
68	Re-estimating annual deaths due to multidrug-resistant organism infections. Infection Control and Hospital Epidemiology, 2019, 40, 112-113.	2.0	97
69	Outcomes Associated With De-escalating Therapy for Methicillin-Resistant Staphylococcus aureus in Culture-Negative Nosocomial Pneumonia. Chest, 2019, 155, 53-59.	0.9	37
70	Postoperative Pneumonia Prevention inÂPulmonary Resections: A Feasibility Pilot Study. Annals of Thoracic Surgery, 2019, 107, 262-270.	1.4	6
71	Rationalizing antimicrobial therapy in the ICU: a narrative review. Intensive Care Medicine, 2019, 45, 172-189.	8.2	164
72	New antibiotics for community-acquired pneumonia. Current Opinion in Infectious Diseases, 2019, 32, 169-175.	3.1	34

#	Article	IF	Citations
73	Antibiotic Thresholds for Sepsis and Septic Shock. Clinical Infectious Diseases, 2019, 69, 938-940.	5.7	4
74	A Hypothesis-Generating Study of the Combination of Aspirin plus Macrolides in Patients with Severe Community-Acquired Pneumonia. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.4	16
75	Duration of Exposure to Antipseudomonal Î²â€Lactam Antibiotics in the Critically Ill and Development of New Resistance. Pharmacotherapy, 2019, 39, 261-270.	2.7	126
76	2226. Impact of Prior and Concomitant Antibacterial Therapy on Outcomes in the ASPECT-NP Randomized, Controlled Trial of Ceftolozane/Tazobactam (C/T) vs. Meropenem (MEM) in Patients with Ventilated Nosocomial Pneumonia (NP). Open Forum Infectious Diseases, 2019, 6, S760-S760.	0.9	0
77	Reply to MacFadden et al. Clinical Infectious Diseases, 2018, 66, 479-480.	5.7	0
78	Sepsis-Associated Coagulopathy Severity Predicts Hospital Mortality*. Critical Care Medicine, 2018, 46, 736-742.	0.9	96
79	Importance of Site of Infection and Antibiotic Selection in the Treatment of Carbapenem-Resistant Pseudomonas aeruginosa Sepsis. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.4	22
80	Treatment of severe skin and soft tissue infections: a review. Current Opinion in Infectious Diseases, 2018, 31, 113-119.	3.1	39
81	Readmissions With Multidrug-Resistant Infection in Patients With Prior Multidrug Resistant Infection. Infection Control and Hospital Epidemiology, 2018, 39, 12-19.	2.0	18
82	Thirty-day hospital readmissions among mechanically ventilated emergency department patients. Emergency Medicine Journal, 2018, 35, 252-256.	2.0	5
83	The Burden of Viruses in Pneumonia Associated With Acute Respiratory Failure. Chest, 2018, 154, 84-90.	0.9	44
84	Acinetobacter Pneumonia: Improving Outcomes With Early Identification and Appropriate Therapy. Clinical Infectious Diseases, 2018, 67, 1455-1462.	5.7	29
85	Clinical epidemiology of carbapenem-resistant gram-negative sepsis among hospitalized patients: Shifting burden of disease?. American Journal of Infection Control, 2018, 46, 1092-1096.	2.5	13
86	Infectious Diseases Consultation Reduces 30-Day and 1-Year All-Cause Mortality for Multidrug-Resistant Organism Infections. Open Forum Infectious Diseases, 2018, 5, ofy026.	0.9	71
87	Frequent Versus Infrequent Monitoring of Endotracheal Tube Cuff Pressures. Respiratory Care, 2018, 63, 495-501.	1.8	34
88	Dilution Factor of Quantitative Bacterial Cultures Obtained by Bronchoalveolar Lavage in Patients with Ventilator-Associated Bacterial Pneumonia. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.4	10
89	qSOFA score: Predictive validity in Enterobacteriaceae bloodstream infections. Journal of Critical Care, 2018, 43, 143-147.	2.3	10
90	Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial. Lancet Infectious Diseases, The, 2018, 18, 285-295.	8.9	315

#	Article	IF	Citations
91	Monocyte Function and Clinical Outcomes in Febrile and Afebrile Patients With Severe Sepsis. Shock, 2018, 50, 381-387.	2.1	28
92	Risk Factors and Outcomes for Ineffective Empiric Treatment of Sepsis Caused by Gram-Negative Pathogens: Stratification by Onset of Infection. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.4	16
93	1008. Cluster Analysis to Define Distinct Clinical Phenotypes Among Septic Patients With Bloodstream Infections. Open Forum Infectious Diseases, 2018, 5, S300-S300.	0.9	0
94	2521 Use of forced air warming devices to induce fever-range hyperthermia in critically ill septic patients. Journal of Clinical and Translational Science, 2018, 2, 50-50.	0.7	0
95	Catheter removal and outcomes of multidrug-resistant central-line-associated bloodstream infection. Medicine (United States), 2018, 97, e12782.	1.1	33
96	1894. Antimicrobial Stewardship in the Intensive Care Unit: Survey of Critical Care and Infectious Diseases Physicians. Open Forum Infectious Diseases, 2018, 5, S543-S543.	0.9	0
97	872. PROPHETIC: Predicting Pneumonia in Hospitalized Patients in the ICUâ€"A Model and Scoring System. Open Forum Infectious Diseases, 2018, 5, S25-S25.	0.9	0
98	Is Zero Ventilator-Associated Pneumonia Achievable?. Clinics in Chest Medicine, 2018, 39, 809-822.	2.2	17
99	The most recent concepts for the management of bacterial and fungal infections in ICU. Intensive Care Medicine, 2018, 44, 2000-2003.	8.2	6
100	Prevention of hospital-acquired pneumonia. Current Opinion in Critical Care, 2018, 24, 370-378.	3.4	33
101	Summary of the international clinical guidelines for the management of hospital-acquired and ventilator-acquired pneumonia. ERJ Open Research, 2018, 4, 00028-2018.	2.7	45
102	Using wearable technology to predict health outcomes: a literature review. Journal of the American Medical Informatics Association: JAMIA, 2018, 25, 1221-1227.	4.6	64
103	Differences in mortality between infections due to extended-spectrum-beta-lactamaseâ€"producing Klebsiella pneumoniae and Escherichia coli. Infection Control and Hospital Epidemiology, 2018, 39, 1138-1139.	2.0	4
104	â€œDoes this patient haveâ€¦â€•â€œIs this patient at risk for infection with multidrug resistant bacteria?â€• Intensive Care Medicine, 2017, 43, 436-439.	8.2	9
105	The intensive care medicine research agenda on multidrug-resistant bacteria, antibiotics, and stewardship. Intensive Care Medicine, 2017, 43, 1187-1197.	8.2	105
106	Association between augmented renal clearance and clinical outcomes in patients receiving Î²-lactam antibiotic therapy by continuous or intermittent infusion: a nested cohort study of the BLING-II randomised, placebo-controlled, clinical trial. International Journal of Antimicrobial Agents, 2017, 49, 624-630.	3.3	83
107	Viruses are prevalent in non-ventilated hospital-acquired pneumonia. Respiratory Medicine, 2017, 122, 76-80.	2.9	58
108	COUNTERPOINT: Should Inhaled Antibiotic Therapy Be Used Routinely for the Treatment of Bacterial Lower Respiratory Tract Infections in the ICU Setting? No. Chest, 2017, 151, 740-743.	0.9	9

#	Article	IF	Citations
109	Rebuttal From Dr Kollef. Chest, 2017, 151, 744-745.	0.9	1
110	Ventilator-Associated Pneumonia: The Role of Emerging Diagnostic Technologies. Seminars in Respiratory and Critical Care Medicine, 2017, 38, 253-263.	2.2	27
111	Prevention of Staphylococcus aureus Ventilator-Associated Pneumonia: Conventional Antibiotics Wonâ€™t Cut It. Clinical Infectious Diseases, 2017, 64, 1089-1091.	5.7	5
112	A Respiratory Therapist Disease Management Program for Subjects Hospitalized With COPD. Respiratory Care, 2017, 62, 1-9.	1.8	23
113	To which extent can we decrease antibiotic duration in critically ill patients?. Expert Review of Clinical Pharmacology, 2017, 10, 1215-1223.	3.2	9
114	Principles of antimicrobial stewardship for bacterial and fungal infections in ICU. Intensive Care Medicine, 2017, 43, 1894-1897.	8.2	2
115	A Prospective One-Year Microbiologic Survey of Combined Pneumonia and Respiratory Failure. Surgical Infections, 2017, 18, 827-833.	1.4	10
116	International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia. European Respiratory Journal, 2017, 50, 1700582.	7.5	877
117	Controversies and advances in the management of ventilator associated pneumonia. Expert Review of Respiratory Medicine, 2017, 11, 875-884.	2.5	13
118	ICD-9-CM Coding for Multidrug Resistant Infection Correlates Poorly With Microbiologically Confirmed Multidrug Resistant Infection. Infection Control and Hospital Epidemiology, 2017, 38, 1381-1383.	2.0	6
119	CAP, HCAP, HAP,ÂVAP. Chest, 2017, 152, 909-910.	0.9	7
120	Predicting Resistance to Piperacillin-Tazobactam, Cefepime and Meropenem in Septic Patients With Bloodstream Infection Due to Gram-Negative Bacteria. Clinical Infectious Diseases, 2017, 65, 1607-1614.	5.7	39
121	A Randomized Trial of the Amikacin Fosfomycin Inhalation System for the Adjunctive Therapy of Gram-Negative Ventilator-Associated Pneumonia. Chest, 2017, 151, 1239-1246.	0.9	138
122	Augmented renal clearance is not a risk factor for mortality in Enterobacteriaceae bloodstream infections treated with appropriate empiric antimicrobials. PLoS ONE, 2017, 12, e0180247.	2.5	10
123	Enhanced antimicrobial de-escalation for pneumonia in mechanically ventilated patients: a cross-over study. Critical Care, 2017, 21, 180.	6.0	23
124	Evaluating the Value of the Respiratory Therapist: Where Is the Evidence? Focus on the Barnes-Jewish Hospital Experience. Respiratory Care, 2017, 62, 1602-1610.	1.8	16
125	Real-time automated clinical deterioration alerts predict thirty-day hospital readmission. Journal of Hospital Medicine, 2016, 11, 768-772.	1.3	3
126	The Impact of Nighttime Intensivists on Medical Intensive Care Unit Infection-Related Indicators. Infection Control and Hospital Epidemiology, 2016, 37, 352-354.	2.0	5

#	Article	IF	Citations
127	In 2035, will all bacteria be multiresistant? Yes. Intensive Care Medicine, 2016, 42, 2014-2016.	8.2	8
128	A Case-Control Study Assessing the Impact of Nonventilated Hospital-Acquired Pneumonia on Patient Outcomes. Chest, 2016, 150, 1008-1014.	0.9	103
129	Diagnosis and management of skin and soft tissue infections in the intensive care unit: a review. Intensive Care Medicine, 2016, 42, 1899-1911.	8.2	57
130	Secular trends in Acinetobacter baumannii resistance in respiratory and blood stream specimens in the United States, 2003 to 2012: A survey study. Journal of Hospital Medicine, 2016, 11, 21-26.	1.3	88
131	Impact of Time to Appropriate Therapy on Mortality in Patients with Vancomycin-Intermediate Staphylococcus aureus Infection. Antimicrobial Agents and Chemotherapy, 2016, 60, 5546-5553.	3.4	16
132	A targeted educational intervention to reduce ventilator-associated complications. American Journal of Infection Control, 2016, 44, 1406-1407.	2.5	3
133	Use of a Shared Canister Protocol for the Delivery of Metered-Dose Inhalers in Mechanically Ventilated Subjects. Respiratory Care, 2016, 61, 1285-1292.	1.8	4
134	Editorial Commentary: Antimicrobial De-escalation: What's in a Name?. Clinical Infectious Diseases, 2016, 62, 1018-1020.	5.7	8
135	Randomized Controlled Trial to Determine the Impact of Probiotic Administration on Colonization With Multidrug-Resistant Organisms in Critically Ill Patients. Infection Control and Hospital Epidemiology, 2015, 36, 1451-1454.	2.0	25
136	Pseudomonas aeruginosaNosocomial Pneumonia: Impact of Pneumonia Classification. Infection Control and Hospital Epidemiology, 2015, 36, 1190-1197.	2.0	35
137	Targeted Fluid Minimization Following Initial Resuscitation in Septic Shock. Chest, 2015, 148, 1462-1469.	0.9	64
138	Pneumonia Pathogen Characterization Is an Independent Determinant of Hospital Readmission. Chest, 2015, 148, 103-111.	0.9	27
139	An international multicenter retrospective study of Pseudomonas aeruginosa nosocomial pneumonia: impact of multidrug resistance. Critical Care, 2015, 19, 219.	6.0	214
140	Impact of antibacterials on subsequent resistance and clinical outcomes in adult patients with viral pneumonia: an opportunity for stewardship. Critical Care, 2015, 19, 404.	6.0	33
141	Outcomes associated with bacteremia in the setting of methicillin-resistant Staphylococcus aureus pneumonia: a retrospective cohort study. Critical Care, 2015, 19, 312.	6.0	15
142	Impact of Sepsis Classification and Multidrug-Resistance Status on Outcome Among Patients Treated With Appropriate Therapy*. Critical Care Medicine, 2015, 43, 1580-1586.	0.9	59
143	Risk factors for 30â€day readmission among patients with cultureâ€positive severe sepsis and septic shock: A retrospective cohort study. Journal of Hospital Medicine, 2015, 10, 678-685.	1.3	15
144	Update on ventilator-associated pneumonia. Current Opinion in Critical Care, 2015, 21, 430-438.	3.4	26

#	Article	IF	Citations
145	Clinical effectiveness of a sedation protocol minimizing benzodiazepine infusions and favoring early dexmedetomidine: a before-after study. Critical Care, 2015, 19, 136.	6.0	17
146	A Prospective Evaluation of Ventilator-Associated Conditions and Infection-Related Ventilator-Associated Conditions. Chest, 2015, 147, 68-81.	0.9	106
147	Ten old antibiotics that will never disappear. Intensive Care Medicine, 2015, 41, 1950-1953.	8.2	1
148	Surveillance versus clinical adjudication: Differences persist with new ventilator-associated event definition. American Journal of Infection Control, 2015, 43, 589-591.	2.5	15
149	The Use of Inhaled Prostaglandins in Patients With ARDS. Chest, 2015, 147, 1510-1522.	0.9	113
150	Ventilator-associated Pneumonia Prevention. Is It Worth It?. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 5-7.	6.6	10
151	Management of Infections with Drug-Resistant Organisms in Critical Care. Clinics in Chest Medicine, 2015, 36, 531-541.	2.2	6
152	Development and validation of a clinical prediction rule for candidemia in hospitalized patients with severe sepsis and septic shock. Journal of Critical Care, 2015, 30, 715-720.	2.3	28
153	The number of discharge medications predicts thirty-day hospital readmission: a cohort study. BMC Health Services Research, 2015, 15, 282.	2.2	77
154	If antibiotics did not exist. Intensive Care Medicine, 2015, 41, 525-527.	8.2	1
155	1233A Comparison of National Healthcare Safety Network (NHSN) Ventilator Associated Pneumonia (VAP) and Ventilator Associated Event (VAE) Definitions. Open Forum Infectious Diseases, 2014, 1, S45-S45.	0.9	2
156	1658C. difficile Recurrence is a Strong Predictor of 30-day Rehospitalization Among ICU Patients. Open Forum Infectious Diseases, 2014, 1, S443-S443.	0.9	0
157	881New Ventilator Associated Event (VAE) Definition: Persistence of Subjective Variability. Open Forum Infectious Diseases, 2014, 1, S253-S253.	0.9	0
158	A randomized trial of realâ€time automated clinical deterioration alerts sent to a rapid response team. Journal of Hospital Medicine, 2014, 9, 424-429.	1.3	81
159	Treatment of gram - positive infections in critically ill patients. BMC Infectious Diseases, 2014, 14, 92.	3.0	33
160	Predictors of Outcome in 216 Subjects With ARDS Treated With Inhaled Epoprostenol. Respiratory Care, 2014, 59, 1178-1185.	1.8	23
161	Telavancin for Hospital-Acquired Pneumonia: Clinical Response and 28-Day Survival. Antimicrobial Agents and Chemotherapy, 2014, 58, 2030-2037.	3.4	56
162	Rational Use of Antibiotics in the ICU. JAMA - Journal of the American Medical Association, 2014, 312, 1403.	7.0	26

#	Article	IF	Citations
163	Multi-drug resistance, inappropriate initial antibiotic therapy and mortality in Gram-negative severe sepsis and septic shock: a retrospective cohort study. Critical Care, 2014, 18, 596.	6.0	256
164	Reducing the Burden of Acute Respiratory Distress Syndrome. Shock, 2014, 41, 378-387.	2.1	21
165	Global Prospective Epidemiologic and Surveillance Study of Ventilator-Associated Pneumonia due to Pseudomonas aeruginosa*. Critical Care Medicine, 2014, 42, 2178-2187.	0.9	163
166	Identifying Critically Ill Patients at Risk for Inappropriate Antibiotic Therapy. Critical Care Medicine, 2014, 42, 1832-1838.	0.9	21
167	Using the Number Needed to Treat to Assess Appropriate Antimicrobial Therapy as a Determinant of Outcome in Severe Sepsis and Septic Shock*. Critical Care Medicine, 2014, 42, 2342-2349.	0.9	93
168	Clinical implications for patients treated inappropriately for community-acquired pneumonia in the emergency department. BMC Infectious Diseases, 2014, 14, 61.	3.0	29
169	Conservative fluid therapy in septic shock: an example of targeted therapeutic minimization. Critical Care, 2014, 18, 481.	6.0	10
170	Probiotics for preventing ventilator-associated pneumonia. The Cochrane Library, 2014, 2014, CD009066.	2.8	112
171	Effects of Empiric Antifungal Therapy for Septic Shock on Time to Appropriate Therapy for Candida Infection: A Pilot Study. Clinical Therapeutics, 2014, 36, 1226-1232.	2.3	10
172	What can be expected from antimicrobial de-escalation in the critically ill?. Intensive Care Medicine, 2014, 40, 92-95.	8.2	16
173	Candidemia and non-candidemia related septic shock: are there differences between them?. Intensive Care Medicine, 2014, 40, 1046-1048.	8.2	3
174	Ventilator-Associated Pneumonia Prevention. Chest, 2014, 146, 873-874.	0.9	3
175	Ventilator-associated Complications, Including Infection-related Complications. Critical Care Clinics, 2013, 29, 33-50.	2.4	22
176	A risk score for identifying methicillin-resistant Staphylococcus aureus in patients presenting to the hospital with pneumonia. BMC Infectious Diseases, 2013, 13, 268.	3.0	67
177	Determinants of Hospital Mortality Among Patients with Sepsis or Septic Shock Receiving Appropriate Antibiotic Treatment. Current Infectious Disease Reports, 2013, 15, 400-406.	3.2	11
178	Prolonged Infusion Antibiotics for Suspected Gram-Negative Infections in the ICU: A Before-After Study. Annals of Pharmacotherapy, 2013, 47, 170-180.	2.1	44
179	Azithromycin and survival inStreptococcus pneumoniaepneumonia: a retrospective study. BMJ Open, 2013, 3, e002898.	2.1	12
180	Aerosolized antibiotics. Current Opinion in Infectious Diseases, 2013, 26, 538-544.	3.1	45

#	Article	IF	Citations
181	Developing a New, National Approach to Surveillance for Ventilator-Associated Events*. Critical Care Medicine, 2013, 41, 2467-2475.	0.9	635
182	Readmission Following Hospitalization for Pneumonia: The Impact of Pneumonia Type and Its Implication for Hospitals. Clinical Infectious Diseases, 2013, 57, 362-367.	5.7	49
183	Developing a New, National Approach to Surveillance for Ventilator-Associated Events: Executive Summary. Clinical Infectious Diseases, 2013, 57, 1742-1746.	5.7	56
184	Fluid balance and cardiac function in septic shock as predictors of hospital mortality. Critical Care, 2013, 17, R246.	6.0	128
185	Ventilator-Associated Tracheobronchitis and Ventilator-Associated Pneumonia. Chest, 2013, 144, 3-5.	0.9	3
186	Short- vs Long-Duration Antibiotic Regimens for Ventilator-Associated Pneumonia. Chest, 2013, 144, 1759-1767.	0.9	131
187	Probiotics for Ventilator-Associated Pneumonia. Chest, 2013, 143, 590-592.	0.9	4
188	Preventive Strategies in VAP: Focus on Silver-Coated Endotracheal Tubes. , 2013, , 531-555.		2
189	Patients Hospitalized With Pneumonia: Determining the Need for Broad-Spectrum Antibiotic Therapy. Clinical Infectious Diseases, 2012, 54, 479-482.	5.7	6
190	Use of Adjunctive Aerosolized Antimicrobial Therapy in the Treatment ofPseudomonas aeruginosaandAcinetobacter baumanniiVentilator-Associated Pneumonia. Respiratory Care, 2012, 57, 1226-1233.	1.8	84
191	Validation of a Clinical Score for Assessing the Risk of Resistant Pathogens in Patients With Pneumonia Presenting to the Emergency Department. Clinical Infectious Diseases, 2012, 54, 193-198.	5.7	151
192	Septic Shock Attributed to Candida Infection: Importance of Empiric Therapy and Source Control. Clinical Infectious Diseases, 2012, 54, 1739-1746.	5.7	386
193	A comparison of ventilator-associated pneumonia rates as identified according to the National Healthcare Safety Network and American College of Chest Physicians criteria*. Critical Care Medicine, 2012, 40, 281-284.	0.9	116
194	The determinants of hospital mortality among patients with septic shock receiving appropriate initial antibiotic treatment*. Critical Care Medicine, 2012, 40, 2016-2021.	0.9	69
195	Prevention of ventilator-associated pneumonia or ventilator-associated complications. Critical Care Medicine, 2012, 40, 271-277.	0.9	29
196	Antimicrobial stewardship programs: mandatory for all ICUs. Critical Care, 2012, 16, 179.	6.0	37
197	A randomized trial of 7-day doripenem versus 10-day imipenem-cilastatin for ventilator-associated pneumonia. Critical Care, 2012, 16, R218.	6.0	178
198	Risk Factors for Mixed Complicated Skin and Skin Structure Infections To Help Tailor Appropriate Empiric Therapy. Surgical Infections, 2012, 13, 377-382.	1.4	11

#	Article	IF	Citations
199	Economic Impact of Ventilator-Associated Pneumonia in a Large Matched Cohort. Infection Control and Hospital Epidemiology, 2012, 33, 250-256.	2.0	312
200	Linezolid in Methicillin-Resistant Staphylococcus aureus Nosocomial Pneumonia: A Randomized, Controlled Study. Clinical Infectious Diseases, 2012, 54, 621-629.	5.7	522
201	An institutional perspective on the impact of recent antibiotic exposure on length of stay and hospital costs for patients with gram-negative sepsis. BMC Infectious Diseases, 2012, 12, 56.	3.0	34
202	Telavancin versus Vancomycin for Hospital-Acquired Pneumonia due to Gram-positive Pathogens. Clinical Infectious Diseases, 2011, 52, 31-40.	5.7	242
203	Healthcare-Associated Pneumonia: Approach to Management. Clinics in Chest Medicine, 2011, 32, 507-515.	2.2	8
204	Medical Data Mining for Early Deterioration Warning in General Hospital Wards. , 2011, , .		26
205	Healthcare-associated pneumonia: Diagnostic criteria and distinction from community-acquired pneumonia. International Journal of Infectious Diseases, 2011, 15, e545-e550.	3.3	56
206	Implementation of a real-time computerized sepsis alert in nonintensive care unit patients*. Critical Care Medicine, 2011, 39, 469-473.	0.9	149
207	Impact of previous antibiotic therapy on outcome of Gram-negative severe sepsis*. Critical Care Medicine, 2011, 39, 1859-1865.	0.9	88
208	Inappropriate antibiotic therapy in Gram-negative sepsis increases hospital length of stay*. Critical Care Medicine, 2011, 39, 46-51.	0.9	165
209	Health Care-Associated Pneumonia (HCAP). Medicine (United States), 2011, 90, 390-395.	1.1	40
210	Hospital-acquired pneumonia/ventilator-associated pneumonia prevention: Truth or dare!*. Critical Care Medicine, 2011, 39, 2015-2016.	0.9	0
211	Clostridium difficile in the ICU. Chest, 2011, 140, 1643-1653.	0.9	63
212	Ventilator-Associated Tracheobronchitis in a Mixed Surgical and Medical ICU Population. Chest, 2011, 139, 513-518.	0.9	84
213	Institutional Perspective on the Impact of Positive Blood Cultures on the Economic and Clinical Outcomes of Patients With Complicated Skin and Skin Structure Infections: Focus on Gram-Positive Infections. Clinical Therapeutics, 2011, 33, 1759-1768.e1.	2.3	2
214	Epidemiology, microbiology and outcomes of healthcare-associated and community-acquired bacteremia: A multicenter cohort study. Journal of Infection, 2011, 62, 130-135.	3.4	90
215	Resistance to empiric antimicrobial treatment predicts outcome in severe sepsis associated with gramâ€negative bacteremia. Journal of Hospital Medicine, 2011, 6, 405-410.	1.3	60
216	Antibiotic Stewardship in the Intensive Care Unit. Seminars in Respiratory and Critical Care Medicine, 2011, 32, 215-227.	2.2	41

#	Article	IF	Citations
217	Diagnostic Utility of Plasma Procalcitonin for Nosocomial Pneumonia in the Intensive Care Unit Setting. Respiratory Care, 2011, 56, 412-419.	1.8	31
218	Appraising Contemporary Strategies to Combat Multidrug Resistant Gram-Negative Bacterial Infectionsâ€"Proceedings and Data From the Gram-Negative Resistance Summit. Clinical Infectious Diseases, 2011, 53, S33-S55.	5.7	89
219	Prevention of Nosocomial Pneumonia in the Intensive Care Unit: Beyond the Use of Bundles. Surgical Infections, 2011, 12, 211-220.	1.4	24
220	Recognition of Nosocomial Pneumonia in the Intensive Care Unit: Still a Confusing Issue. Respiratory Care, 2011, 56, 1209-1212.	1.8	3
221	Early Deterioration Warning for Hospitalized Patients by Mining Clinical Data. International Journal of Knowledge Discovery in Bioinformatics, 2011, 2, 1-20.	0.8	6
222	Activity of a silver-coated endotracheal tube in preclinical models of ventilator-associated pneumonia and a study after extubation*. Critical Care Medicine, 2010, 38, 1135-1140.	0.9	59
223	Recognition and prevention of nosocomial pneumonia in the intensive care unit and infection control in mechanical ventilation. Critical Care Medicine, 2010, 38, S352-S362.	0.9	63
224	Methicillin-resistant Staphylococcus aureus nasal colonization is a poor predictor of intensive care unit-acquired methicillin-resistant Staphylococcus aureus infections requiring antibiotic treatment. Critical Care Medicine, 2010, 38, 1991-1995.	0.9	62
225	A Comparison of Culture-Positive and Culture-Negative Health-Care-Associated Pneumonia. Chest, 2010, 137, 1130-1137.	0.9	88
226	A magic bullet for sepsis: Getting back to the basics*. Critical Care Medicine, 2010, 38, 733-734.	0.9	0
227	The Resuscitation Package in Sepsis. Current Infectious Disease Reports, 2010, 12, 368-373.	3.2	1
228	Hospital Resource Utilization and Costs of Inappropriate Treatment of Candidemia. Pharmacotherapy, 2010, 30, 361-368.	2.7	82
229	Hospitalizations with healthcareâ€associated complicated skin and skin structure infections: Impact of inappropriate empiric therapy on outcomes. Journal of Hospital Medicine, 2010, 5, 535-540.	1.3	42
230	Probiotic Prophylaxis of Ventilator-associated Pneumonia. American Journal of Respiratory and Critical Care Medicine, 2010, 182, 1058-1064.	6.6	314
231	Review of Recent Clinical Trials of Hospitalâ€Acquired Pneumonia and Ventilatorâ€Associated Pneumonia: A Perspective from Academia. Clinical Infectious Diseases, 2010, 51, S29-S35.	5.7	21
232	Methicillin-Resistant Staphylococcus aureus (MRSA) Nasal Colonization Predicts Intensive Care Unit-Acquired MRSA Infections: True Or False?. Surgical Infections, 2010, 11, 497-499.	1.4	7
233	Association Between a Silver-Coated Endotracheal Tube and Reduced Mortality in Patients With Ventilator-Associated Pneumonia. Chest, 2010, 137, 1015-1021.	0.9	62
234	Increased Mortality in Patients Without Ventilator-Associated Pneumonia: Response. Chest, 2010, 138, 1275.	0.9	3

#	Article	IF	Citations
235	Health Care-Associated Pneumonia. Hospital Practice (1995), 2010, 38, 63-74.	1.0	4
236	Economic Burden of Ventilator-Associated Pneumonia Based on Total Resource Utilization. Infection Control and Hospital Epidemiology, 2010, 31, 509-515.	2.0	106
237	Staphylococcus aureusNasal Colonization and Subsequent Infection in Intensive Care Unit Patients: Does Methicillin Resistance Matter?. Infection Control and Hospital Epidemiology, 2010, 31, 584-591.	2.0	91
238	Predicting Bacteremia among Patients Hospitalized for Skin and Skin-Structure Infections: Derivation and Validation of a Risk Score. Infection Control and Hospital Epidemiology, 2010, 31, 828-837.	2.0	30
239	Medical resource utilization among patients with ventilator-associated pneumonia: pooled analysis of randomized studies of doripenem versus comparators. Critical Care, 2010, 14, R84.	6.0	10
240	Will procalcitonin reduce antibiotic use in intensive care?. Lancet, The, 2010, 375, 435-436.	12.1	10
241	Empiric Combination Antibiotic Therapy Is Associated with Improved Outcome against Sepsis Due to Gram-Negative Bacteria: a Retrospective Analysis. Antimicrobial Agents and Chemotherapy, 2010, 54, 1742-1748.	3.4	223
242	Bacteremia Increases the Risk of Death among Patients with Soft-Tissue Infections. Surgical Infections, 2010, 11, 169-176.	1.4	15
243	Health-Care-Associated Pneumonia. Chest, 2009, 135, 594-596.	0.9	4
244	The Importance of Fluid Management in Acute Lung Injury Secondary to Septic Shock. Chest, 2009, 136, 102-109.	0.9	439
245	Clinical Practice Improvement Initiatives. Chest, 2009, 136, 335-338.	0.9	5
246	The Flood and Ebb of Septic Shock: Response. Chest, 2009, 136, 1705-1706.	0.9	0
247	The Alphabet Soup of Pneumonia: CAP, HAP, HCAP, NHAP, and VAP. Seminars in Respiratory and Critical Care Medicine, 2009, 30, 003-009.	2.2	62
248	Severe hospital-acquired pneumonia: A review for clinicians. Current Infectious Disease Reports, 2009, 11, 349-356.	3.2	8
249	Candidemia on presentation to the hospital: development and validation of a risk score. Critical Care, 2009, 13, R156.	6.0	36
250	Diagnostic Implications of Soluble Triggering Receptor Expressed on Myeloid Cells-1 in BAL Fluid of Patients With Pulmonary Infiltrates in the ICU. Chest, 2009, 135, 641-647.	0.9	75
251	Cost-Effectiveness Analysis of a Silver-Coated Endotracheal Tube to Reduce the Incidence of Ventilator-Associated Pneumonia. Infection Control and Hospital Epidemiology, 2009, 30, 759-763.	2.0	68
252	Epidemiology and Outcomes of Hospitalizations with Complicated Skin and Skin-Structure Infections: Implications of Healthcare-Associated Infection Risk Factors. Infection Control and Hospital Epidemiology, 2009, 30, 1203-1210.	2.0	50

#	Article	IF	Citations
253	Implementing quality improvements in the intensive care unit: Ventilator bundle as an example. Critical Care Medicine, 2009, 37, 305-309.	0.9	85
254	Hospital-wide impact of a standardized order set for the management of bacteremic severe sepsis*. Critical Care Medicine, 2009, 37, 819-824.	0.9	105
255	Oral Decontamination to Prevent Ventilator-Associated Pneumonia. Chest, 2009, 135, 1116-1118.	0.9	10
256	VAT vs VAP. Chest, 2009, 135, 252-255.	0.9	11
257	Epidemiology and Outcomes of Clostridium difficile -Associated Disease Among Patients on Prolonged Acute Mechanical Ventilation. Chest, 2009, 136, 752-758.	0.9	45
258	Soluble Triggering Receptor Expressed on Myeloid Cells 1 and the Diagnosis of Ventilator-Associated Pneumonia: Response. Chest, 2009, 136, 320.	0.9	3
259	Health careâ€“associated pneumonia: identification and initial management in the ED. American Journal of Emergency Medicine, 2008, 26, 1-11.	1.7	112
260	Secular Trends in Candidemia-Related Hospitalization in the United States, 2000â€“2005. Infection Control and Hospital Epidemiology, 2008, 29, 978-980.	2.0	125
261	Silver-Coated Endotracheal Tubes and Incidence of Ventilator-Associated Pneumonia. JAMA - Journal of the American Medical Association, 2008, 300, 805.	7.0	416
262	Introduction: Update on the Appropriate Use of Meropenem for the Treatment of Serious Bacterial Infections. Clinical Infectious Diseases, 2008, 47, S1-S2.	5.7	10
263	Antimicrobial Therapy Escalation and Hospital Mortality Among Patients With Health-Care-Associated Pneumonia. Chest, 2008, 134, 963-968.	0.9	134
264	Health Careâ€“Associated Pneumonia (HCAP): A Critical Appraisal to Improve Identification, Management, and Outcomesâ€”Proceedings of the HCAP Summit. Clinical Infectious Diseases, 2008, 46, S296-S334.	5.7	111
265	Pneumonia Caused by Methicillinâ€ResistantStaphylococcus aureus. Clinical Infectious Diseases, 2008, 46, S378-S385.	5.7	299
266	Broadâ€Spectrum Antimicrobials and the Treatment of Serious Bacterial Infections: Getting It Right Up Front. Clinical Infectious Diseases, 2008, 47, S3-S13.	5.7	218
267	Prediction of Infection Due to Antibiotic-Resistant Bacteria by Select Risk Factors for Health Careâ€“Associated Pneumonia. Archives of Internal Medicine, 2008, 168, 2205.	3.7	196
268	Health Careâ€“Associated Infection (HAI): A Critical Appraisal of the Emerging Threatâ€”Proceedings of the HAI Summit. Clinical Infectious Diseases, 2008, 47, S55-S99.	5.7	56
269	SMART Approaches for Reducing Nosocomial Infections in the ICU. Chest, 2008, 134, 447-456.	0.9	39
270	Predictors of 30-Day Mortality and Hospital Costs in Patients With Ventilator-Associated Pneumonia Attributed to Potentially Antibiotic-Resistant Gram-Negative Bacteria. Chest, 2008, 134, 281-287.	0.9	239

#	Article	IF	Citations
271	A 50-Year-Old Woman With Abdominal Pain and Respiratory Failure 3 Months After Kidney Transplantation. Chest, 2008, 134, 442-446.	0.9	16
272	The Modified APACHE II Score Outperforms Curb65 Pneumonia Severity Score as a Predictor of 30-Day Mortality in Patients With Methicillin-Resistant Staphylococcus aureus Pneumonia. Chest, 2008, 133, 363-369.	0.9	38
273	The Importance of Early Treatment With Doxycycline in Human Ehrlichiosis. Medicine (United States), 2008, 87, 53-60.	1.1	58
274	Inappropriate therapy for methicillin-resistant Staphylococcus aureus: Resource utilization and cost implications*. Critical Care Medicine, 2008, 36, 2335-2340.	0.9	72
275	Treatment-related risk factors for hospital mortality in Candida bloodstream infections*. Critical Care Medicine, 2008, 36, 2967-2972.	0.9	161
276	Health Care-Associated Pneumonia and Community-Acquired Pneumonia: a Single-Center Experience. Antimicrobial Agents and Chemotherapy, 2007, 51, 3568-3573.	3.4	370
277	Bugging the Bugs: Novel Approaches in the Strategic Management of Resistant Staphylococcus aureus Infections. Clinical Infectious Diseases, 2007, 45, S163-S164.	5.7	2
278	Optimizing Therapy for MRSA Pneumonia. Seminars in Respiratory and Critical Care Medicine, 2007, 28, 615-623.	2.2	8
279	Addition of Vasopressin to Norepinephrine as Independent Predictor of Mortality in Patients with Refractory Septic Shock: An Observational Study. Surgical Infections, 2007, 8, 189-200.	1.4	20
280	Moving Towards Real-Time Antimicrobial Management of Ventilator-Associated Pneumonia. Clinical Infectious Diseases, 2007, 44, 388-390.	5.7	19
281	Limitations of Vancomycin in the Management of Resistant Staphylococcal Infections. Clinical Infectious Diseases, 2007, 45, S191-S195.	5.7	157
282	Probiotics for Preventing and Treating Nosocomial Infections. Chest, 2007, 132, 286-294.	0.9	54
283	Correctly scoring infections: CSI in the ICU*. Critical Care Medicine, 2007, 35, 2641-2643.	0.9	0
284	Do clinical features allow for accurate prediction of fungal pathogenesis in bloodstream infections? Potential implications of the increasing prevalence of non-albicans candidemia. Critical Care Medicine, 2007, 35, 1077-1083.	0.9	118
285	Economic implications of an evidence-based sepsis protocol: Can we improve outcomes and lower costs?*. Critical Care Medicine, 2007, 35, 1257-1262.	0.9	726
286	A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia. Clinical Therapeutics, 2007, 29, 1107-1115.	2.3	304
287	Use of Hypochlorite Solution to Decrease Rates of Clostridium difficile-Associated Diarrhea. Infection Control and Hospital Epidemiology, 2007, 28, 205-207.	2.0	65
288	The Epidemiology, Pathogenesis and Treatment of Pseudomonas aeruginosa Infections. Drugs, 2007, 67, 351-368.	11.1	725

#	Article	IF	Citations
289	Predictors of In-Hospital Mortality for Bloodstream Infections Caused byEnterobacterSpecies orCitrobacter freundii. Pharmacotherapy, 2007, 27, 191-199.	2.7	38
290	Early Appropriate Empiric Therapy and Antimicrobial De-Escalation. Infectious Disease and Therapy, 2007, , 231-250.	0.0	0
291	The Intensive Care Unit as a Research Laboratory: Developing Strategies to Prevent Antimicrobial Resistance. Surgical Infections, 2006, 7, 85-99.	1.4	5
292	Morbidity and cost burden of methicillin-resistant Staphylococcus aureus in early onset ventilator-associated pneumonia. Critical Care, 2006, 10, R97.	6.0	122
293	Methicillin-resistant Staphylococcus aureus: a new community-acquired pathogen?. Current Opinion in Infectious Diseases, 2006, 19, 161-168.	3.1	63
294	Clinical Characteristics and Treatment Patterns Among Patients With Ventilator-Associated Pneumonia. Chest, 2006, 129, 1210-1218.	0.9	353
295	Time To Get Serious About Infection Prevention in the ICU. Chest, 2006, 130, 1293-1296.	0.9	14
296	Beforeâ€“after study of a standardized hospital order set for the management of septic shock*. Critical Care Medicine, 2006, 34, 2707-2713.	0.9	424
297	Methicillin-resistant Staphylococcus aureus sterile-site infection: The importance of appropriate initial antimicrobial treatment*. Critical Care Medicine, 2006, 34, 2069-2074.	0.9	139
298	Reduced burden of bacterial airway colonization with a novel silver-coated endotracheal tube in a randomized multiple-center feasibility study*. Critical Care Medicine, 2006, 34, 2766-2772.	0.9	145
299	Methicillin-resistant Staphylococcus aureus prolongs intensive care unit stay in ventilator-associated pneumonia, despite initially appropriate antibiotic therapy. Critical Care Medicine, 2006, 34, 700-706.	0.9	131
300	Providing appropriate antimicrobial therapy in the intensive care unit: Surveillance vs. de-escalation*. Critical Care Medicine, 2006, 34, 903-905.	0.9	33
301	Healthcare-associated bloodstream infection: A distinct entity? Insights from a large U.S. database*. Critical Care Medicine, 2006, 34, 2588-2595.	0.9	274
302	Predictors of Mortality for Methicillin-Resistant Staphylococcus aureus Health-Careâ€“Associated Pneumonia. Chest, 2006, 130, 947-955.	0.9	239
303	Optimizing Antibiotic Treatment for Ventilator-Associated Pneumonia. Pharmacotherapy, 2006, 26, 204-213.	2.7	27
304	Microbiological Diagnosis of Ventilator-associated Pneumonia. American Journal of Respiratory and Critical Care Medicine, 2006, 173, 1182-1184.	6.6	13
305	Diagnosis of Ventilator-Associated Pneumonia. New England Journal of Medicine, 2006, 355, 2691-2693.	30.1	61
306	Is Antibiotic Cycling the Answer to Preventing the Emergence of Bacterial Resistance in the Intensive Care Unit?. Clinical Infectious Diseases, 2006, 43, S82-S88.	5.7	81

#	Article	IF	Citations
307	A Randomized Double-Blind Trial of Iseganan in Prevention of Ventilator-associated Pneumonia. American Journal of Respiratory and Critical Care Medicine, 2006, 173, 91-97.	6.6	112
308	Strategies to prevent antimicrobial resistance in the intensive care unit. Critical Care Medicine, 2005, 33, 1845-1853.	0.9	129
309	Invasive approaches to the diagnosis of ventilator-associated pneumonia: A meta-analysis. Critical Care Medicine, 2005, 33, 46-53.	0.9	220
310	Pleuropulmonary Complications of Panton-Valentine Leukocidin-Positive Community-Acquired Methicillin-Resistant Staphylococcus aureus. Chest, 2005, 128, 2732-2738.	0.9	181
311	Antibiotic Utilization and Outcomes for Patients With Clinically Suspected Ventilator-Associated Pneumonia and Negative Quantitative BAL Culture Results. Chest, 2005, 128, 2706-2713.	0.9	110
312	Prevention of hospital infection. Microbes and Infection, 2005, 7, 268-274.	2.0	10
313	The importance of antimicrobial resistance in hospital-acquired and ventilator-associated pneumonia. Current Anaesthesia and Critical Care, 2005, 16, 209-219.	0.3	2
314	Predictors of Hospital Mortality for Patients with Severe Sepsis Treated with Drotrecogin alfa (activated). Pharmacotherapy, 2005, 25, 26-34.	2.7	39
315	Pseudomonas aeruginosaBloodstream Infection: Importance of Appropriate Initial Antimicrobial Treatment. Antimicrobial Agents and Chemotherapy, 2005, 49, 1306-1311.	3.4	489
316	Quinolones for Treatment of Nosocomial Pneumonia: A Meta-Analysis. Clinical Infectious Diseases, 2005, 40, S115-S122.	5.7	24
317	Epidemiology and Outcomes of Health-careâ€“Associated Pneumonia. Chest, 2005, 128, 3854-3862.	0.9	938
318	Transfusion Practice and Blood Stream Infections in Critically Ill Patients. Chest, 2005, 127, 1722-1728.	0.9	115
319	Prevention of Pneumonia in the Hospital Setting. Clinics in Chest Medicine, 2005, 26, 135-142.	2.2	4
320	Gram-Negative Bacterial Resistance: Evolving Patterns and Treatment Paradigms. Clinical Infectious Diseases, 2005, 40, S85-S88.	5.7	33
321	Delaying the Empiric Treatment of Candida Bloodstream Infection until Positive Blood Culture Results Are Obtained: a Potential Risk Factor for Hospital Mortality. Antimicrobial Agents and Chemotherapy, 2005, 49, 3640-3645.	3.4	1,207
322	Bench-to-bedside review: antimicrobial utilization strategies aimed at preventing the emergence of bacterial resistance in the intensive care unit. Critical Care, 2005, 9, 459.	6.0	24
323	Risk Factors for Ventilatorâ€Associated Pneumonia: From Epidemiology to Patient Management. Clinical Infectious Diseases, 2004, 38, 1141-1149.	5.7	260
324	Hospital Mortality for Patients With Bacteremia Due to Staphylococcus aureus or Pseudomonas aeruginosa. Chest, 2004, 125, 607-616.	0.9	157

#	Article	IF	Citations
325	Clinical cure and survival in Gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin. Intensive Care Medicine, 2004, 30, 388-394.	8.2	302
326	A Cost-Benefit Analysis of Gown Use in Controlling Vancomycin-ResistantEnterococcusTransmission Is It Worth the Price?. Infection Control and Hospital Epidemiology, 2004, 25, 418-424.	2.0	68
327	Red blood cell transfusion and ventilator-associated pneumonia: A potential link?. Critical Care Medicine, 2004, 32, 666-674.	0.9	204
328	Prevention of hospital-associated pneumonia and ventilator-associated pneumonia. Critical Care Medicine, 2004, 32, 1396-1405.	0.9	375
329	Cycling empirical antimicrobial agents to prevent emergence of antimicrobial-resistant Gram-negative bacteria among intensive care unit patients. Critical Care Medicine, 2004, 32, 2450-2456.	0.9	105
330	A Randomized Controlled Trial of an Antibiotic Discontinuation Policy for Clinically Suspected Ventilator-Associated Pneumonia. Chest, 2004, 125, 1791-1799.	0.9	352
331	The Effect of an Education Program on the Incidence of Central Venous Catheter-Associated Bloodstream Infection in a Medical ICU. Chest, 2004, 126, 1612-1618.	0.9	236
332	An Educational Intervention to Reduce Ventilator-Associated Pneumonia in an Integrated Health System. Chest, 2004, 125, 2224-2231.	0.9	209
333	Appropriate antibiotic therapy for ventilator-associated pneumonia and sepsis: a necessity, not an issue for debate. Intensive Care Medicine, 2003, 29, 147-149.	8.2	31
334	Management of Severe Sepsis: Integration of Multiple Pharmacologic Interventions. Pharmacotherapy, 2003, 23, 1486-1496.	2.7	16
335	Ventilator-Associated Pneumonia in a Multi-Hospital System Differences in Microbiology by Location. Infection Control and Hospital Epidemiology, 2003, 24, 853-858.	2.0	68
336	Appropriate Empirical Antibacterial Therapy for Nosocomial Infections. Drugs, 2003, 63, 2157-2168.	11.1	124
337	The importance of appropriate initial antibiotic therapy for hospital-acquired infections. American Journal of Medicine, 2003, 115, 582-584.	1.4	98
338	Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia. Clinical Therapeutics, 2003, 25, 980-992.	2.3	227
339	Linezolid vs Vancomycin *. Chest, 2003, 124, 1789-1797.	0.9	592
340	Nursing adherence with evidence-based guidelines for preventing ventilator-associated pneumonia*. Critical Care Medicine, 2003, 31, 2693-2696.	0.9	152
341	Outcome and attributable cost of ventilator-associated pneumonia among intensive care unit patients in a suburban medical center*. Critical Care Medicine, 2003, 31, 1312-1317.	0.9	513
342	Selective Digestive Decontamination Should Not Be Routinely Employed*. Chest, 2003, 123, 464S-468S.	0.9	101

#	Article	IF	Citations
343	Improving Family Communications at the End of Life: Implications for Length of Stay in the Intensive Care Unit and Resource Use. American Journal of Critical Care, 2003, 12, 317-324.	1.7	152
344	Why Do Physicians Not Follow Evidence-Based Guidelines for Preventing Ventilator-Associated Pneumonia?. Chest, 2002, 122, 656-661.	0.9	222
345	Epidemiology and Outcomes of Ventilator-Associated Pneumonia in a Large US Database. Chest, 2002, 122, 2115-2121.	0.9	1,101
346	Effect of an education program aimed at reducing the occurrence of ventilator-associated pneumonia*. Critical Care Medicine, 2002, 30, 2407-2412.	0.9	289
347	Clinical Importance of Delays in the Initiation of Appropriate Antibiotic Treatment for Ventilator-Associated Pneumonia. Chest, 2002, 122, 262-268.	0.9	920
348	Silver-Coated Endotracheal Tubes Associated With Reduced Bacterial Burden in the Lungs of Mechanically Ventilated Dogs. Chest, 2002, 121, 863-870.	0.9	175
349	Early versus late enteral feeding of mechanically ventilated patients: results of a clinical trial. Journal of Parenteral and Enteral Nutrition, 2002, 26, 174-181.	2.7	281
350	Prevention of Antibiotic Resistance in Hospitals. Annals of Internal Medicine, 2002, 136, 173.	10.2	0
351	Antibiotic Resistance in the Intensive Care Unit. Annals of Internal Medicine, 2001, 134, 298.	10.2	387
352	Experience with a clinical guideline for the treatment of ventilator-associated pneumonia. Critical Care Medicine, 2001, 29, 1109-1115.	0.9	541
353	Mechanical Ventilator Weaning Protocols Driven by Nonphysician Health-Care Professionals. Chest, 2001, 120, 454S-463S.	0.9	242
354	The Occurrence of Ventilator-Associated Pneumonia in a Community Hospital. Chest, 2001, 120, 555-561.	0.9	313
355	A Comparative Analysis of Patients With Early-Onset vs Late-Onset Nosocomial Pneumonia in the ICU Setting. Chest, 2000, 117, 1434-1442.	0.9	261
356	Inadequate treatment of nosocomial infections is associated with certain empiric antibiotic choices. Critical Care Medicine, 2000, 28, 3456-3464.	0.9	157
357	Inadequate Antimicrobial Treatment: An Important Determinant of Outcome for Hospitalized Patients. Clinical Infectious Diseases, 2000, 31, S131-S138.	5.7	561
358	The Influence of Inadequate Antimicrobial Treatment of Bloodstream Infections on Patient Outcomes in the ICU Setting. Chest, 2000, 118, 146-155.	0.9	1,657
359	Inadequate Antimicrobial Treatment of Infections. Chest, 1999, 115, 462-474.	0.9	1,753
360	The Prevention of Ventilator-Associated Pneumonia. New England Journal of Medicine, 1999, 340, 627-634.	30.1	508

#	Article	IF	Citations
361	A Randomized Clinical Trial of Continuous Aspiration of Subglottic Secretions in Cardiac Surgery Patients. Chest, 1999, 116, 1339-1346.	0.9	316
362	Effect of a nursing-implemented sedation protocol on the duration of mechanical ventilation. Critical Care Medicine, 1999, 27, 2609-2615.	0.9	1,043
363	A Randomized Clinical Trial Comparing an Extended-Use Hygroscopic Condenser Humidifier With Heated-Water Humidification in Mechanically Ventilated Patients. Chest, 1998, 113, 759-767.	0.9	384
364	A randomized, controlled trial of protocol-directed versus physician-directed weaning from mechanical ventilation. Critical Care Medicine, 1997, 25, 567-574.	0.9	747
365	The Safety and Diagnostic Accuracy of Minibronchoalveolar Lavage in Patients with Suspected Ventilator-Associated Pneumonia. Annals of Internal Medicine, 1995, 122, 743.	10.2	194
366	The Effect of Late-Onset Ventilator-Associated Pneumonia in Determining Patient Mortality. Chest, 1995, 108, 1655-1662.	0.9	379
367	Mechanical Ventilation with or without 7-Day Circuit Changes. Annals of Internal Medicine, 1995, 123, 168.	10.2	152
368	A Persistent Left Lower Lobe Infiltrate and Chronic Cough Following Chest Wounds Sustained in Vietnam Twenty-Four Years Earlier. Military Medicine, 1993, 158, 499-500.	0.9	0
369	Staphylococcal Pneumonia. , 0, , 444-454.		0